Structure guided design of Biotin protein ligase inhibitors for antibiotic discovery

Current Topics in Medicinal Chemistry

Volumn 14, Issue 1, 2014, Pages 4-20

  Paparella, Ashleigh S ^a   Soares da Costa, Tatiana P ^a,c   Yap, Min Y ^b,d   Tieu, William ^a   Wilce, Matthew C J ^b   Booker, Grant W ^a   Abell, Andrew D ^a   Polyak, Steven W ^a  

^a UNIVERSITY OF ADELAIDE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c CHARLES STURT UNIVERSITY   (Australia)

^d CSL LIMITED   (Australia)

Author keywords

Antibiotic; Biotin; Biotin protein ligase; Inhibitor design; Staphylococcus aureus; Structure guided drug design; X ray crystallography

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ADENOSINE PHOSPHATE; ADENOSINE TRIPHOSPHATE; BIOTIN; BIOTIN PROTEIN LIGASE INHIBITOR; CAP BINDING PROTEIN; LIGASE INHIBITOR; PYRUVATE CARBOXYLASE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL SURVIVAL; BACTERIAL VIRULENCE; BIOTINYLATION; CARBOXY TERMINAL SEQUENCE; DRUG DESIGN; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGH THROUGHPUT SEQUENCING; HUMAN; LIGAND BINDING; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; NUCLEOTIDE BINDING SITE; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; STAPHYLOCOCCUS AUREUS; SURFACE PLASMON RESONANCE; X RAY CRYSTALLOGRAPHY;

ACETYL-COA CARBOXYLASE; ADENOSINE TRIPHOSPHATE; ANTI-BACTERIAL AGENTS; BIOTIN; CARBON-NITROGEN LIGASES; CATALYTIC DOMAIN; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG DISCOVERY; ENZYME INHIBITORS; ESCHERICHIA COLI PROTEINS; MOLECULAR TARGETED THERAPY; PROTEIN CONFORMATION; REPRESSOR PROTEINS; STAPHYLOCOCCUS AUREUS;

EID: 84891753304     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026613666131111103149     Document Type: Article

References (130)

1. Boucher, H.W.; Talbot, G.H.; Bradley, J.S.; Edwards, J.E.; Gilbert, D.; Rice, L.B.; Scheld, M.; Spellberg, B.; Bartlett, J. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis., 2009, 48 (1), 1-12.
2. Lewis, K. Antibiotics: Recover the lost art of drug discovery. Nature, 2012, 485 (7399), 439-40.
3. Cooper, M.A.; Shlaes, D. Fix the antibiotics pipeline. Nature, 2011, 472 (7341), 32.
4. Butler, M.S.; Cooper, M.A. Antibiotics in the clinical pipeline in 2011. J. Antibiot. (Tokyo), 2011, 64 (6), 413-25.
5. Coates, A.R.; Halls, G. Antibiotics in phase II and III clinical trials. Handb. Exp. Pharmacol., 2012, 211, 167-83.
6. Fischbach, M.A.; Walsh, C.T. Antibiotics for emerging pathogens. Science, 2009, 325 (5944), 1089-93.
7. Lewis, K. Platforms for antibiotic discovery. Nat. Rev. Drug Discov., 2013, 12 (5), 371-87.
8. Payne, D.J.; Gwynn, M.N.; Holmes, D.J.; Pompliano, D.L. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov., 2007, 6 (1), 29-40.
9. Archer, G.L. Staphylococcus aureus: a well-armed pathogen. Clin. Infect. Dis., 1998, 26 (5), 1179-81.
10. Grundmann, H.; Aires-de-Sousa, M.; Boyce, J.; Tiemersma, E. Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat. Lancet, 2006, 368 (9538), 874-85.
11. Weidenmaier, C.; Goerke, C.; Wolz, C. Staphylococcus aureus determinants for nasal colonization. Trends Microbiol., 2012, 20 (5), 243-50.
12. Lowy, F.D. Staphylococcus aureus infections. N. Engl. J. Med., 1998, 339 (8), 520-32.
13. Tong, S.Y.; Chen, L.F.; Fowler, V.G., Jr. Colonization, pathogenicity, host susceptibility, and therapeutics for Staphylococcus aureus: what is the clinical relevance? Semin. Immunopathol., 2012, 34 (2), 185-200.
14. Chambers, H.F. Methicillin-resistant staphylococci. Clin. Microbiol. Rev., 1988, 1 (2), 173-86.
15. Otto, M. Community-associated MRSA: What makes them special? Int. J. Med. Microbiol., 2013, 303 (6-7), 324-330.
16. Sievert, D.M.; Ricks, P.; Edwards, J.R.; Schneider, A.; Patel, J.; Srinivasan, A.; Kallen, A.; Limbago, B.; Fridkin, S. Antimicrobialresistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol., 2013, 34 (1), 1-14.
17. de Kraker, M.E.; Davey, P.G.; Grundmann, H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med., 2011, 8 (10), e1001104.
18. de Kraker, M.E.; Wolkewitz, M.; Davey, P.G.; Koller, W.; Berger, J.; Nagler, J.; Icket, C.; Kalenic, S.; Horvatic, J.; Seifert, H.; Kaasch, A.J.; Paniara, O.; Argyropoulou, A.; Bompola, M.; Smyth, E.; Skally, M.; Raglio, A.; Dumpis, U.; Kelmere, A.M.; Borg, M.; Xuereb, D.; Ghita, M.C.; Noble, M.; Kolman, J.; Grabljevec, S.; Turner, D.; Lansbury, L.; Grundmann, H. Clinical impact of antimicrobial resistance in European hospitals: excess mortality and length of hospital stay related to methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob. Agents Chemother., 2011, 55 (4), 1598-605.
19. Holmes, N.E.; Turnidge, J.D.; Munckhof, W.J.; Robinson, J.O.; Korman, T.M.; O'Sullivan, M.V.; Anderson, T.L.; Roberts, S.A.; Gao, W.; Christiansen, K.J.; Coombs, G.W.; Johnson, P.D.; Howden, B.P. Antibiotic choice may not explain poorer outcomes in patients with Staphylococcus aureus bacteremia and high vancomycin minimum inhibitory concentrations. J. Infect. Dis., 2011, 204 (3), 340-7.
20. Turnidge, J.D.; Kotsanas, D.; Munckhof, W.; Roberts, S.; Bennett, C.M.; Nimmo, G.R.; Coombs, G.W.; Murray, R.J.; Howden, B.; Johnson, P.D.; Dowling, K. Staphylococcus aureus bacteraemia: a major cause of mortality in Australia and New Zealand. Med. J. Aust., 2009, 191 (7), 368-73.
21. Nimmo, G.R.; Coombs, G.W.; Pearson, J.C.; O'Brien, F.G.; Christiansen, K.J.; Turnidge, J.D.; Gosbell, I.B.; Collignon, P.; McLaws, M.L. Methicillin-resistant Staphylococcus aureus in the Australian community: an evolving epidemic. Med. J. Aust., 2006, 184 (8), 384-8.
22. Weigel, L.M.; Clewell, D.B.; Gill, S.R.; Clark, N.C.; McDougal, L.K.; Flannagan, S.E.; Kolonay, J.F.; Shetty, J.; Killgore, G.E.; Tenover, F.C. Genetic analysis of a high-level vancomycinresistant isolate of Staphylococcus aureus. Science, 2003, 302 (5650), 1569-71.
23. Klein, E.; Smith, D.L.; Laxminarayan, R. Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005. Emerg. Infect. Dis., 2007, 13 (12), 1840-6.
24. Forsyth, R.A.; Haselbeck, R.J.; Ohlsen, K.L.; Yamamoto, R.T.; Xu, H.; Trawick, J.D.; Wall, D.; Wang, L.; Brown-Driver, V.; Froelich, J.M.; Keder, G.C.; King, P.; McCarthy, M.; Malone, C.; Misiner, B.; Robbins, D.; Tan, Z.; Zhu Zy, Z.Y.; Carr, G.; Mosca, D.A.; Zamudio, C.; Foulkes, J.G.; Zyskind, J.W. A genome-wide strategy for the identification of essential genes in Staphylococcus aureus. Mol. Microbiol., 2002, 43 (6), 1387-400.
25. Barker, D.F.; Campbell, A.M. Genetic and biochemical characterisation of the birA gene and its product: Evidence for a direct role of biotin holoenzyme synthetase in repression of the biotin operon in Escherichia coli. J. Mol. Biol., 1981, 146, 469-492.
26. Chapman-Smith, A.; Turner, D.L.; Cronan, J.E.; Morris, T.W.; Wallace, J.C. Expression, biotinylation and purification of a biotin-domain peptide from the biotin carboxy carrier protein of Escherichia coli acetyl-CoA carboxylase. Biochem. J., 1994, 302 (3), 881-887.
27. Gerdes, S.Y.; Scholle, M.D.; Campbell, J.W.; Balazsi, G.; Ravasz, E.; Daugherty, M.D.; Somera, A.L.; Kyrpides, N.C.; Anderson, I.; Gelfand, M.S.; Bhattacharya, A.; Kapatral, V.; D'Souza, M.; Baev, M.V.; Grechkin, Y.; Mseeh, F.; Fonstein, M.Y.; Overbeek, R.; Barabasi, A.L.; Oltvai, Z.N.; Osterman, A.L. Experimental determination and system level analysis of essential genes in Escherichia coli MG1655. J. Bacteriol., 2003, 185 (19), 5673-84.
28. Duckworth, B.P.; Geders, T.W.; Tiwari, D.; Boshoff, H.I.; Sibbald, P.A.; Barry, C.E., 3rd; Schnappinger, D.; Finzel, B.C.; Aldrich, C.C. Bisubstrate adenylation inhibitors of biotin protein ligase from Mycobacterium tuberculosis. Chem. Biol., 2011, 18 (11), 1432-41.
29. Thanassi, J.A.; Hartman-Neumann, S.L.; Dougherty, T.J.; Dougherty, B.A.; Pucci, M.J. Identification of 113 conserved essential genes using a high-throughput gene disruption system in Streptococcus pneumoniae. Nucleic Acids Res., 2002, 30 (14), 3152-62.
30. Polyak, S.W.; Bailey, L.M.; Azhar, A.; Booker, G.W., Biotin (Vitamin H or B7). In Micronutrients: Sources, properties and health benefits. Eds Betancourt, A.I.; Gaitan, H.F. Nova Science Publishers: New York, USA., 2012; pp 65-94.
31. Waldrop, G.L.; Holden, H.M.; St Maurice, M. The enzymes of biotin dependent CO (2) metabolism: what structures reveal about their reaction mechanisms. Protein Sci., 2012, 21 (11), 1597-619.
32. St Maurice, M.; Reinhardt, L.; Surinya, K.H.; Attwood, P.V.; Wallace, J.C.; Cleland, W.W.; Rayment, I. Domain architecture of pyruvate carboxylase, a biotin-dependent multifunctional enzyme. Science, 2007, 317 (5841), 1076-9.
33. Tong, L. Structure and function of biotin-dependent carboxylases. Cell. Mol. Life Sci., 2013, 70 (5), 863-91.
34. Attwood, P.V. The structure and mechanism of action of pyruvate carboxylase. Int. J. Biochem. Cell Biol., 1995, 27, 231-249.
35. Cronan, J.E., Jr.; Waldrop, G.L. Multi-subunit acetyl-CoA carboxylases. Prog. Lipid Res., 2002, 41 (5), 407-35.
36. White, S.W.; Zheng, J.; Zhang, Y.M.; Rock The structural biology of type II fatty acid biosynthesis. Annu. Rev. Biochem., 2005, 74, 791-831.
37. Campbell, J.W.; Cronan, J.E., Jr. Bacterial fatty acid biosynthesis: targets for antibacterial drug discovery. Annu. Rev. Microbiol., 2001, 55, 305-32.
38. Polyak, S.W.; Abell, A.D.; Wilce, M.C.; Zhang, L.; Booker, G.W. Structure, function and selective inhibition of bacterial acetyl-CoA carboxylase. Appl. Microbiol. Biotechnol., 2012, 93 (3), 983-92.
39. Wright, H.T.; Reynolds, K.A. Antibacterial targets in fatty acid biosynthesis. Curr. Opin. Microbiol., 2007, 10 (5), 447-53.
40. Parsons, J.B.; Rock, C.O. Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery? Curr. Opin. Microbiol., 2011, 14 (5), 544-9.
41. Raetz, C.R.; Reynolds, C.M.; Trent, M.S.; Bishop, R.E. Lipid A modification systems in Gram-negative bacteria. Annu. Rev. Biochem., 2007, 76, 295-329.
42. Brinster, S.; Lamberet, G.; Staels, B.; Trieu-Cuot, P.; Gruss, A.; Poyart, C. Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. Nature, 2009, 458 (7234), 83-6.
43. Balemans, W.; Lounis, N.; Gilissen, R.; Guillemont, J.; Simmen, K.; Andries, K.; Koul, A. Essentiality of FASII pathway for Staphylococcus aureus. Nature, 2010, 463 (7279), E3-4.
44. Brinster, S.; Lamberet, G.; Staels, B.; Trieu-Cuot, P.; Gruss, A.; Poyart, C. Brinster et al. Reply. Nature, 2010, 463 (E4-E4).
45. Parsons, J.B.; Frank, M.W.; Subramanian, C.; Saenkham, P.; Rock, C.O. Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors. Proc. Natl. Acad. Sci. U S A, 2011, 108 (37), 15378-83.
46. Payne, D.J.; Miller, W.H.; Berry, V.; Brosky, J.; Burgess, W.J.; Chen, E.; DeWolf Jr, W.E., Jr.; Fosberry, A.P.; Greenwood, R.; Head, M.S.; Heerding, D.A.; Janson, C.A.; Jaworski, D.D.; Keller, P.M.; Manley, P.J.; Moore, T.D.; Newlander, K.A.; Pearson, S.; Polizzi, B.J.; Qiu, X.; Rittenhouse, S.F.; Slater-Radosti, C.; Salyers, K.L.; Seefeld, M.A.; Smyth, M.G.; Takata, D.T.; Uzinskas, I.N.; Vaidya, K.; Wallis, N.G.; Winram, S.B.; Yuan, C.C.; Huffman, W.F. Discovery of a novel and potent class of FabIdirected antibacterial agents. Antimicrob. Agents Chemother., 2002, 46 (10), 3118-24.
47. Freiberg, C.; Brunner, N.A.; Schiffer, G.; Lampe, T.; Pohlmann, J.; Brands, M.; Raabe, M.; Habich, D.; Ziegelbauer, K. Identification and characterization of the first class of potent bacterial acetyl-CoA carboxylase inhibitors with antibacterial activity. J. Biol. Chem., 2004, 279 (25), 26066-73.
48. Miller, W.H.; Seefeld, M.A.; Newlander, K.A.; Uzinskas, I.N.; Burgess, W.J.; Heerding, D.A.; Yuan, C.C.; Head, M.S.; Payne, D.J.; Rittenhouse, S.F.; Moore, T.D.; Pearson, S.C.; Berry, V.; DeWolf, W.E., Jr.; Keller, P.M.; Polizzi, B.J.; Qiu, X.; Janson, C.A.; Huffman, W.F. Discovery of aminopyridine-based inhibitors of bacterial enoyl-ACP reductase (FabI). J. Med. Chem., 2002, 45 (15), 3246-56.
49. Miller, J.R.; Dunham, S.; Mochalkin, I.; Banotai, C.; Bowman, M.; Buist, S.; Dunkle, B.; Hanna, D.; Harwood, H.J.; Huband, M.D.; Karnovsky, A.; Kuhn, M.; Limberakis, C.; Liu, J.Y.; Mehrens, S.; Mueller, W.T.; Narasimhan, L.; Ogden, A.; Ohren, J.; Prasad, J.V.; Shelly, J.A.; Skerlos, L.; Sulavik, M.; Thomas, V.H.; Vander-Roest, S.; Wang, L.; Wang, Z.; Whitton, A.; Zhu, T.; Stover, C.K. A class of selective antibacterials derived from a protein kinase inhibitor pharmacophore. Proc. Natl. Acad. Sci. U S A, 2009, 106 (6), 1737-42.
50. Wang, J.; Soisson, S.M.; Young, K.; Shoop, W.; Kodali, S.; Galgoci, A.; Painter, R.; Parthasarathy, G.; Tang, Y.S.; Cummings, R.; Ha, S.; Dorso, K.; Motyl, M.; Jayasuriya, H.; Ondeyka, J.; Herath, K.; Zhang, C.; Hernandez, L.; Allocco, J.; Basilio, A.; Tormo, J.R.; Genilloud, O.; Vicente, F.; Pelaez, F.; Colwell, L.; Lee, S.H.; Michael, B.; Felcetto, T.; Gill, C.; Silver, L.L.; Hermes, J.D.; Bartizal, K.; Barrett, J.; Schmatz, D.; Becker, J.W.; Cully, D.; Singh, S.B. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature, 2006, 441 (7091), 358-61.
51. Jitrapakdee, S.; St Maurice, M.; Rayment, I.; Cleland, W.W.; Wallace, J.C.; Attwood, P.V. Structure, mechanism and regulation of pyruvate carboxylase. Biochem. J., 2008, 413 (3), 369-87.
52. Jitrapakdee, S.; Wallace, J.C. Structure, function and regulation of pyruvate carboxylase. Biochem. J., 1999, 340 (1), 1-16.
53. Somerville, G.A.; Proctor, R.A. At the crossroads of bacterial metabolism and virulence factor synthesis in Staphylococci. Microbiol. Mol. Biol. Rev., 2009, 73 (2), 233-48.
54. Sonenshein, A.L. Control of key metabolic intersections in Bacillus subtilis. Nat. Rev. Microbiol., 2007, 5 (12), 917-27.
55. Dunn, M.F. Tricarboxylic acid cycle and anaplerotic enzymes in rhizobia. FEMS Microbiol. Rev., 1998, 22 (2), 105-23.
56. Petersen, S.; de Graaf, A.A.; Eggeling, L.; Mollney, M.; Wiechert, W.; Sahm, H. In vivo quantification of parallel and bidirectional fluxes in the anaplerosis of Corynebacterium glutamicum. J. Biol. Chem., 2000, 275 (46), 35932-41.
57. Chaudhuri, R.R.; Allen, A.G.; Owen, P.J.; Shalom, G.; Stone, K.; Harrison, M.; Burgis, T.A.; Lockyer, M.; Garcia-Lara, J.; Foster, S.J.; Pleasance, S.J.; Peters, S.E.; Maskell, D.J.; Charles, I.G. Comprehensive identification of essential Staphylococcus aureus genes using Transposon-Mediated Differential Hybridisation (TMDH). BMC Genomics, 2009, 10, 291.
58. Bae, T.; Banger, A.K.; Wallace, A.; Glass, E.M.; Aslund, F.; Schneewind, O.; Missiakas, D.M. Staphylococcus aureus virulence genes identified by Bursa aurealis mutagenesis and nematode killing. Proc. Natl. Acad. Sci. U S A, 2004, 101 (33), 12312-7.
59. Gretler, A.C.; Mucciolo, P.; Evans, J.B.; Niven, C.F. Vitamin nutrition of the Staphylococci with special reference to their biotin requirements. J. Bacteriol., 1955, 70, 44-49.
60. Porter, J.R.; Pelczar, M.J., Jr. Biotin (Bios Iib, Vitamin H)-an essential growth factor for certain staphylococci. Science, 1940, 91 (2372), 576-577.
61. Hugo, W.B.; Davidson, J.R. Effect of cell lipid depletion in Staphylococcus aureus upon its resistance to antimicrobial agents 1. Lipid depletion induced by biotin deficiency Microbios, 1973, 8, 43-51.
62. Adekeye, J.D.; Coles, E.H. Effect of biotin deficiency on some properties of Staphylococcus aureus isolates from humans and other animals. Infect. Immun., 1976, 13 (2), 475-479.
63. Baltz, R.H. Daptomycin: mechanisms of action and resistance, and biosynthetic engineering. Curr. Opin. Chem. Biol., 2009, 13 (2), 144-51.
64. Fedtke, I.; Gotz, F.; Peschel, A. Bacterial evasion of innate host defenses-the Staphylococcus aureus lesson. Int. J. Med. Microbiol., 2004, 294 (2-3), 189-94.
65. Kraus, D.; Peschel, A. Staphylococcus aureus evasion of innate antimicrobial defense. Future Microbiol., 2008, 3, 437-51.
66. Sahm, H.; Eggeling, L.; de Graaf, A.A. Pathway analysis and metabolic engineering in Corynebacterium glutamicum. Biol. Chem., 2000, 381 (9-10), 899-910.
67. Pfefferle, W.; Mockel, B.; Bathe, B.; Marx, A. Biotechnological manufacture of lysine. Adv. Biochem. Eng. Biotechnol., 2003, 79, 59-112.
68. Bagautdinov, B.; Kuroishi, C.; Sugahara, M.; Kunishima, N. Crystal structures of biotin protein ligase from Pyrococcus horikoshii OT3 and its complexes: structural basis of biotin activation. J. Mol. Biol., 2005, 353 (2), 322-33.
69. Bagautdinov, B.; Matsuura, Y.; Bagautdinova, S.; Kunishima, N. Protein biotinylation visualized by a complex structure of biotin protein ligase with a substrate. J. Biol. Chem., 2008, 283 (21), 14739-50.
70. Beckett, D. Biotin sensing at the molecular level. J. Nutr., 2009, 139 (1), 167-70.
71. Campeau, E.; Gravel, R.A. Expression in Escherichia coli of Nand C-terminally deleted human holocarboxylase synthetase. Influence of the N-terminus on biotinylation and identification of a minimum functional protein. J. Biol. Chem., 2001, 276 (15), 12310-6.
72. Mayende, L.; Swift, R.D.; Bailey, L.M.; Soares da Costa, T.P.; Wallace, J.C.; Booker, G.W.; Polyak, S.W. A novel molecular mechanism to explain biotin-unresponsive holocarboxylase synthetase deficiency. J. Mol. Med., 2012, 90 (1), 81-8.
73. Pendini, N.R.; Bailey, L.M.; Booker, G.W.; Wilce, M.C.; Wallace, J.C.; Polyak, S.W. Biotin protein ligase from Candida albicans: expression, purification and development of a novel assay. Arch. Biochem. Biophys., 2008, 479 (2), 163-9.
74. Polyak, S.W.; Chapman-Smith, A.; Brautigan, P.J.; Wallace, J.C. Biotin protein ligase from Saccharomyces cerevisiae. The Nterminal domain is required for complete activity. J. Biol. Chem., 1999, 274 (46), 32847-54.
75. Hassan, Y.I.; Moriyama, H.; Olsen, L.J.; Bi, X.; Zempleni, J. Nand C-terminal domains in human holocarboxylase synthetase participate in substrate recognition. Mol. Genet. Metab., 2009, 96 (4), 183-8.
76. Lee, C.K.; Cheong, C.; Jeon, Y.H. The N-terminal domain of human holocarboxylase synthetase facilitates biotinylation via direct interaction with the substrate protein. FEBS Lett., 2010, 584 (4), 675-80.
77. Wilson, K.P.; Shewchuk, L.M.; Brennan, R.G.; Otsuka, A.J.; Matthews, B.W. Escherichia coli biotin holoenzyme synthetase/ bio repressor crystal structure delineates the biotin-and DNA-binding domains. Proc. Natl. Acad. Sci. U S A, 1992, 89, 9257-9261.
78. Weaver, L.H.; Kwon, K.; Beckett, D.; Matthews, B.W. Corepressor-induced organization and assembly of the biotin repressor: a model for allosteric activation of a transcriptional regulator. Proc. Natl. Acad. Sci. U S A, 2001, 98 (11), 6045-50.
79. Wood, Z.A.; Weaver, L.H.; Brown, P.H.; Beckett, D.; Matthews, B.W. Co-repressor induced order and biotin repressor dimerization: a case for divergent followed by convergent evolution. J. Mol. Biol., 2006, 357 (2), 509-23.
80. Tron, C.M.; McNae, I.W.; Nutley, M.; Clarke, D.J.; Cooper, A.; Walkinshaw, M.D.; Baxter, R.L.; Campopiano, D.J. Structural and functional studies of the biotin protein ligase from Aquifex aeolicus reveal a critical role for a conserved residue in target specificity. J. Mol. Biol., 2009, 387 (1), 129-46.
81. Pendini, N.R.; Yap, M.Y.; Polyak, S.W.; Cowieson, N.P.; Abell, A.; Booker, G.W.; Wallace, J.C.; Wilce, J.A.; Wilce, M.C. Structural characterization of Staphylococcus aureus biotin protein ligase and interaction partners: An antibiotic target. Protein Sci, 2013, 22 (6), 762-73.
82. Pendini, N.R.; Polyak, S.W.; Booker, G.W.; Wallace, J.C.; Wilce, M.C. Purification, crystallization and preliminary crystallographic analysis of biotin protein ligase from Staphylococcus aureus. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun., 2008, 64 (Pt 6), 520-3.
83. Kwon, K.; Beckett, D. Function of a conserved sequence motif in biotin holoenzyme synthetases. Protein Sci., 2000, 9 (8), 1530-9.
84. Xu, Y.; Beckett, D. Kinetics of biotinyl-5'-adenylate synthesis catalyzed by the Escherichia coli repressor of biotin biosynthesis and the stability of the enzyme-product complex. Biochemistry, 1994, 33 (23), 7354-7360.
85. Choi-Rhee, E.; Schulman, H.; Cronan, J.E. Promiscuous protein biotinylation by Escherichia coli biotin protein ligase. Protein Sci., 2004, 13 (11), 3043-50.
86. Naganathan, S.; Beckett, D. Nucleation of an allosteric response via ligand-induced loop folding. J. Mol. Biol., 2007, 373 (1), 96-111.
87. Streaker, E.D.; Beckett, D. Ligand-linked structural changes in the Escherichia coli biotin repressor: the significance of surface loops for binding and allostery. J. Mol. Biol., 1999, 292 (3), 619-32.
88. Kumar, N.; Shukla, S.; Kumar, S.; Suryawanshi, A.; Chaudhry, U.; Ramachandran, S.; Maiti, S. Intrinsically disordered protein from a pathogenic mesophile Mycobacterium tuberculosis adopts structured conformation at high temperature. Proteins, 2008, 71 (3), 1123-33.
89. Noble, M.E.M.; Musacchio, A.; Saraste, M.; Courtneidge, S.A.; Wierenga, R.K. Crystal structure of the SH3 domain in human Fyn-Comparison of the 3-dimensional structures of SH3 domains in tyrosine kinases and spectrin. EMBO J., 1993, 12 (7), 2617-2624.
90. Chapman-Smith, A.; Mulhern, T.D.; Whelan, F.; Cronan, J.E., Jr.; Wallace, J.C. The C-terminal domain of biotin protein ligase from E. coli is required for catalytic activity. Protein Sci., 2001, 10 (12), 2608-17.
91. Chapman-Smith, A.; Cronan, J.E.J. The enzymatic biotinylation of proteins: a post-translational modification of exceptional specificity. Trends Biochem. Sci., 1999, 24, 359-363.
92. Pendini, N.R.; Bailey, L.M.; Booker, G.W.; Wilce, M.C.; Wallace, J.C.; Polyak, S.W. Microbial biotin protein ligases aid in understanding holocarboxylase synthetase deficiency. Biochim. Biophys. Acta, 2008, 1784 (7-8), 973-82.
93. Athappilly, F.K.; Hendrickson, W.A. Structure of the biotinyl domain of acetyl-coenzyme A carboxylase determined by MAD phasing. Structure, 1995, 3 (12), 1407-1419.
94. Roberts, E.L.; Shu, N.C.; Howard, M.J.; Broadhurst, R.W.; Chapman-Smith, A.; Wallace, J.C.; Morris, T.; Cronan, J.E.; Perham, R.N. Solution structures of apo and holo biotinyl domains from acetyl coenzyme A carboxylase of Escherichia coli determined by triple-resonance nuclear magnetic resonance spectroscopy. Biochemistry, 1999, 38 (16), 5045-5053.
95. Reche, P.; Li, Y.L.; Fuller, C.; Eichhorn, K.; Perham, R.N. Selectivity of post-translational modification in biotinylated proteins-the carboxy carrier protein of the acetyl-CoA carboxylase of Escherichia coli. Biochem. J., 1998, 329 (3), 589-596.
96. Reche, P.; Perham, R.N. Structure and selectivity in posttranslational modification: attaching the biotinyl-lysine and lipoyllysine swinging arms in multifunctional enzymes. EMBO J., 1999, 18, 2673-2682.
97. Leon-Del-Rio, A.; Gravel, R.A. Sequence requirements for the biotinylation of carboxyl-terminal fragments of human propionyl-CoA carboxylase alpha subunit expressed in Escherichia coli. J. Biol. Chem., 1994, 269 (37), 22964-22968.
98. Polyak, S.W.; Chapman-Smith, A.; Mulhern, T.D.; Cronan, J.E., Jr.; Wallace, J.C. Mutational analysis of protein substrate presentation in the post-translational attachment of biotin to biotin domains. J. Biol. Chem., 2001, 276 (5), 3037-45.
99. Shenoy, B.C.; Wood, H.G. Effect of mutations at Met-88 and Met-90 on the biotination of Lys-89 of the apo 1. 3S subunit of transcarboxylase. FASEB J., 1988, 2, 2396-2401.
100. Shenoy, B.C.; Xie, Y.; Park, V.L.; Kumar, G.K.; Beegan, H.; Wood, H.G.; Samols, D. The importance of methionine residues for the catalysis of the biotin enzyme, transcarboxylase. J. Biol. Chem., 1992, 267 (26), 18407-18412.
101. Kondo, H.; Uno, S.; Komizo, Y.Y.; Sunamoto, J. Importance of methionine residues in the enzymatic carboxylation of biotin containing peptides representing the local bindyl site of E. coli actyl CoA carboxylase. Int. J. Peptide Protein Res., 1984, 23, 559-564.
102. Hanka, L.J.; Bergy, M.E.; Kelly, R.B. Naturally occurring antimetabolite antibiotic related to biotin. Science, 1966, 154 (757), 1667-8.
103. Hanka, L.J.; Martin, D.G.; Reineke, L.M. Two new antimetabolites of biotin: alpha-methyldethiobiotin and alpha-methylbiotin. Antimicrob. Agents Chemother., 1972, 1 (2), 135-8.
104. Piffeteau, A.; Dufour, M.N.; Zamboni, M.; Gaudry, M.; Marquet, A. Mechanism of the antibiotic action of alpha-dehydrobiotin. Biochemistry, 1980, 19 (13), 3069-73.
105. Amspacher, D.R.; Blanchard, C.Z.; Fronczek, F.R.; Saraiva, M.C.; Waldrop, G.L.; Strongin, R.M. Synthesis of a reaction intermediate analogue of biotin-dependent carboxylases via a selective derivatization of biotin. Org. Lett., 1999, 1 (1), 99-102.
106. Blanchard, C.Z.; Amspacher, D.; Strongin, R.; Waldrop, G.L. Inhibition of biotin carboxylase by a reaction intermediate analog: implications for the kinetic mechanism. Biochem. Biophys. Res. Commun., 1999, 266 (2), 466-71.
107. Slavoff, S.A.; Chen, I.; Choi, Y.A.; Ting, A.Y. Expanding the substrate tolerance of biotin ligase through exploration of enzymes from diverse species. J. Am. Chem. Soc., 2008, 130 (4), 1160-2.
108. Soares da Costa, T.P.; Tieu, W.; Yap, M.Y.; Pendini, N.R.; Polyak, S.W.; Sejer Pedersen, D.; Morona, R.; Turnidge, J.D.; Wallace, J.C.; Wilce, M.C.; Booker, G.W.; Abell, A.D. Selective inhibition of Biotin protein ligase from Staphylococcus aureus. J. Biol. Chem., 2012, 287 (21), 17823-32.
109. Soares da Costa, T.P.; Tieu, W.; Yap, M.Y.; Zvarec, O.; Bell, J.; Turnidge, J.D.; Wallace, J.C.; Booker, G.W.; Wilce, M.C.J.; Abell, A.D.; Polyak, S.W. Biotin analogues with antibacterial activity are potent inhibitors of Biotin protein ligase. ACS Med. Chem. Lett., 2012, 3, 509-514.
110. Xu, Y.; Nenortas, E.; Beckett, D. Evidence for distinct ligandbound conformational states of the multifunctional Escherichia coli repressor of biotin biosynthesis. Biochemistry, 1995, 34 (51), 16624-16631.
111. Lu, H.; England, K.; am Ende, C.; Truglio, J.J.; Luckner, S.; Reddy, B.G.; Marlenee, N.L.; Knudson, S.E.; Knudson, D.L.; Bowen, R.A.; Kisker, C.; Slayden, R.A.; Tonge, P.J. Slow-onset inhibition of the FabI enoyl reductase from Francisella tularensis: residence time and in vivo activity. ACS Chem. Biol., 2009, 4 (3), 221-31.
112. Artymiuk, P.J.; Rice, D.W.; Poirrette, A.R.; Willet, P. A tale of two synthetases. Nat. Struct. Biol., 1994, 1 (11), 758-760.
113. Reche, P.A. Lipoylating and biotinylating enzymes contain a homologous catalytic module. Protein Sci., 2000, 9 (10), 1922-9.
114. Bernier, S.; Akochy, P.M.; Lapointe, J.; Chenevert, R. Synthesis and aminoacyl-tRNA synthetase inhibitory activity of aspartyl adenylate analogs. Bioorg. Med. Chem., 2005, 13 (1), 69-75.
115. Bottcher, C.; Dennis, E.G.; Booker, G.W.; Polyak, S.W.; Boss, P.K.; Davies, C. A novel tool for studying auxin-metabolism: the inhibition of grapevine indole-3-acetic Acid-amido synthetases by a reaction intermediate analogue. PLoS One, 2012, 7 (5), e37632.
116. Forrest, A.K.; Jarvest, R.L.; Mensah, L.M.; O'Hanlon, P.J.; Pope, A.J.; Sheppard, R.J. Aminoalkyl adenylate and aminoacyl sulfamate intermediate analogues differing greatly in affinity for their cognate Staphylococcus aureus aminoacyl tRNA synthetases. Bioorg. Med. Chem. Lett., 2000, 10 (16), 1871-4.
117. Lee, J.; Kang, S.U.; Kang, M.K.; Chun, M.W.; Jo, Y.J.; Kwak, J.H.; Kim, S. Methionyl adenylate analogues as inhibitors of methionyl-tRNA synthetase. Bioorg. Med. Chem. Lett., 1999, 9 (10), 1365-70.
118. Patrone, J.D.; Yao, J.; Scott, N.E.; Dotson, G.D. Selective inhibitors of bacterial phosphopantothenoylcysteine synthetase. J. Am. Chem. Soc., 2009, 131 (45), 16340-1.
119. Tian, Y.; Suk, D.H.; Cai, F.; Crich, D.; Mesecar, A.D. Bacillus anthracis o-succinylbenzoyl-CoA synthetase: reaction kinetics and a novel inhibitor mimicking its reaction intermediate. Biochemistry, 2008, 47 (47), 12434-47.
120. Yu, X.Y.; Hill, J.M.; Yu, G.; Wang, W.; Kluge, A.F.; Wendler, P.; Gallant, P. Synthesis and structure-activity relationships of a series of novel thiazoles as inhibitors of aminoacyl-tRNA synthetases. Bioorg. Med. Chem. Lett., 1999, 9 (3), 375-80.
121. Brown, P.H.; Cronan, J.E.; Grotli, M.; Beckett, D. The biotin repressor: modulation of allostery by corepressor analogs. J. Mol. Biol., 2004, 337 (4), 857-69.
122. Purushothaman, S.; Gupta, G.; Srivastava, R.; Ramu, V.G.; Surolia, A. Ligand specificity of group I biotin protein ligase of Mycobacterium tuberculosis. PLoS One, 2008, 3 (5), e2320.
123. Meldal, M.; Tornoe, C.W. Cu-catalyzed azide-alkyne cycloaddition. Chem. Rev., 2008, 108 (8), 2952-3015.
124. Rostovtsev, V.V.; Green, L.G.; Fokin, V.V.; Sharpless, K.B. A stepwise huisgen cycloaddition process: copper (I)-catalyzed regioselective "ligation" of azides and terminal alkynes. Angew. Chem. Int. Ed. Engl., 2002, 41 (14), 2596-9.
125. Whiting, M.; Muldoon, J.; Lin, Y.C.; Silverman, S.M.; Lindstrom, W.; Olson, A.J.; Kolb, H.C.; Finn, M.G.; Sharpless, K.B.; Elder, J.H.; Fokin, V.V. Inhibitors of HIV-1 protease by using in situ click chemistry. Angew. Chem. Int. Ed. Engl., 2006, 45 (9), 1435-9.
126. Tieu, W.; Soares da Costa, T.P.; Yap, M.Y.; Keeling, K.L.; Wilce, M.C.J.; Wallace, J.C.; Booker, G.W.; Polyak, S.W.; Abell, A.D. Optimising in situ click chemistry: the screening and identification of biotin protein ligase inhibitors. Chem. Sci., 2013, 4, 3533-3537.
127. Zhang, L.; Chen, X.; Xue, P.; Sun, H.H.; Williams, I.D.; Sharpless, K.B.; Fokin, V.V.; Jia, G. Ruthenium-catalyzed cycloaddition of alkynes and organic azides. J. Am. Chem. Soc., 2005, 127 (46), 15998-9.
128. Sharpless, K.B.; Manetsch, R. In situ click chemistry: a powerful means for lead discovery. Expert. Opin. Drug. Discov., 2006, 1 (6), 525-38.
129. Thirumurugan, P.; Matosiuk, D.; Jozwiak, K. Click chemistry for drug development and diverse chemical-biology applications. Chem. Rev., 2013, 113 (7), 4905-4979.
130. Manetsch, R.; Krasinski, A.; Radic, Z.; Raushel, J.; Taylor, P.; Sharpless, K.B.; Kolb, H.C. In situ click chemistry: enzyme inhibitors made to their own specifications. J. Am. Chem. Soc., 2004, 126 (40), 12809-18.